Personalis, Inc. (PSNL)
Analyzes cancer DNA to detect recurrence and guide personalized treatment decisions.
$11.80-0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+118.9%
The outlook
PSNL is trading at $11.80, positioned solidly above its 50- and 200-day moving averages and roughly midway through its 52-week range. Analyst consensus leans Buy, with an average price target about 18% above the current level. The stock's technical positioning and analyst outlook both show constructive signals.
What’s behind the score
Analyst consensusBuy — 1.7 avg of 4 analysts
Price trendAbove its 50- & 200-day averages
52-week range63% of the way from its 52-week low to high
Price targetAvg target +18% vs current price
Analyst price target
~12-month · 4 analysts$13.88average target+17.6% vs now
Now $11.80
Low $10.00High $16.25
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.26B
52-wk high
$16.39
52-wk low
$3.84
50-day avg
$11.43
200-day avg
$8.97
Trailing P/E
—